Asset profile

Human Acellular Vessel (Humacyte)

Other

Weaksignal

Evidence outlook · lead readout

NCT01872208 · Peripheral Arterial Disease, Peripheral Vascular Disease

The reported results come from study designs that frequently fail to replicate under controlled conditions — see the rationale below.

NCT01872208: All 20 patients received the same implant with no comparison group and no blinding, so there is nothing to show whether outcomes differ from standard bypass surgery or from chance. Results have not yet been posted.

How the evidence outlook works ↗

Upcoming events

(1 total)

Estimated primary-completion dates from ClinicalTrials.gov — registry estimates, never confirmed readout dates; they can move as trials progress.

2030 (1)
September 2030 (1)
Phase 2Atherosclerotic Cardiovascular DiseaseNot yet recruiting
Est. primary completion 2030-09 · NCT07730528 · CT.gov ↗
What to watch

Research analysis

Source-grounded endpoint goals, benchmarks, comparator context, and caveats for this readout are included with Research.

See the full readout calendar ↗

All registered studies

Research

Unlock the complete ClinicalTrials.gov registry

Research includes every linked study, indication filters, phase grouping and featured-trial cross-links.

Competitive landscape

Research

Unlock the competitor landscape

Research compares assets by shared mechanism and indication, including each competitor's stage in the relevant market.